Park and Sonpavde on Sacituzumab Govitecan Plus Enfortumab Vedotin in Metastatic Urothelial Cancer

Author(s):

Chandler Park, MD, MSc, FACPGuru Sonpavde, MD

Fact checked by:

Drs Park and Sonpavde discuss findings from the phase 1 DAD trial, as well as a schema for the frontline management of metastatic urothelial carcinoma.

In Oncology Unplugged, a podcast series from MedNews Week, host Chandler Park, MD, a genitourinary (GU) medical oncologist at the Norton Cancer Institute in Louisville, Kentucky, invites guests to dive deep into pivotal trial data, treatment recommendations, and ongoing research across oncology specialties.

In the final part of a 3-part series, Dr Park converses with Guru Sonpavde, MD, about findings from the phase 1 DAD trial (NCT04724018), which evaluated sacituzumab govitecan-hziy (Trodelvy) plus enfortumab vedotin-ejfv (Padcev) in patients with pretreated metastatic urothelial cancer, as well as Dr Sonpavde's proposed schema for the frontline management of metastatic urothelial carcinoma. Dr Sonpavde is the medical director of GU Oncology, the assistant director of the Clinical Research Unit, and the Christopher K. Glanz Chair for Bladder Cancer Research at AdventHealth Cancer Institute in Orlando, Florida.

Drs Park and Sonpavde discuss current frontline treatment considerations for patients with advanced urothelial carcinoma, expand on results from the DAD trial, and highlight the planned DAD-IO extension of the study, which will investigate the combination of sacituzumab govitecan, enfortumab vedotin, and pembrolizumab (Keytruda) for the first-line treatment of patients with metastatic urothelial cancer.